-
Recent Posts
Categories
- Anesthesiology
- Avandia
- Biomedical Engineering
- Cardiology
- Clinical Trials
- Clinics
- Consumer Products
- Counterfeit Products
- Critical Care Medicine
- Dentistry
- Dermatology
- Emergency Rooms
- Endocrinology
- Eye Care
- Family Practice
- FDA 2011
- FDA 2012
- FDA 2013
- FDA Label Change
- FDA Notice
- FDA Recall
- FDA Safety Communication
- FDA Warning
- Gastroenterology
- Healthcare Professionals
- Hematology
- Home Care
- Hospitals
- Infectious Disease
- Internal Medicine
- Laboratory
- multiple sclerosis (MS)
- Nephrology
- Neurology
- Nursing
- OBGYN
- Oncology
- Ophthalmology
- Orthopaedic Surgery
- Pain Management
- Patients
- Pediatrics
- Pharmacy
- Physical Medicine
- Psychiatry
- Pulmonology
- Radiology
- Rheumatology
- Risk Manager
- Surgery
- Uncategorized
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
Category Archives: Nephrology
Samsca tolvaptan Drug Warning
Samsca (tolvaptan): Drug Warning – Potential Risk of Liver Injury AUDIENCE: Gastroenterology, Nephrology, Pharmacy ISSUE: Otsuka and FDA notified healthcare professionals of significant liver injury associated with the use of Samsca. In a double-blind, 3-year, placebo-controlled trial in about 1400 … Continue reading
Posted in FDA 2013, FDA Warning, Gastroenterology, Nephrology, Pharmacy
Tagged drug risks, Drug Warning, FDA notice, FDA warning, Gastroenterology, Nephrology, Pharmacy, Risk of Liver Injury, Samsca, Samsca tolvaptan Drug Warning, tolvaptan
Comments Off
Cefepime Label Change drug risks
Cefepime:Label Change- Risk of Seizure in Patients Not Receiving Dosage Adjustments for Kidney Impairment Audience: Health Professional,Infectious Disease, Nephrology Issue: There have been cases of a specific type of seizure called nonconvulsive status epilepticus associated with the use of … Continue reading
Posted in FDA 2012, FDA Warning, Healthcare Professionals, Infectious Disease, Nephrology
Tagged Adverse Effects, Cefepime, Cefepime Label Change, drug effects, drug reactions, drug risks, FDA warning, Health Professional, Infectious Disease, Nephrology, Risk of Seizure, safety label changes
Comments Off
Dialysate Concentrates Used in Hemodialysis Safety Communication
Dialysate Concentrates Used in Hemodialysis: Safety Communication – Alkali Dosing Errors AUDIENCE: Nephrology, Nursing ISSUE: FDA is notifying health care providers to consider the presence and quantity of acetate, citrate, and/or acetic acid in dialysate concentrates when determining the patients’ … Continue reading